ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
20.094,95
0,93%
S&P 500
5.942,47
0,00%
Dow Jones
42.732,13
0,00%
Euro vs US Dollar
1,0426
1,17%
Bitcoin
99.327,32
1,02%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Tango Therapeutics Inc (TNGX)

  7. Tango Therapeutics Inc (TNGX) News

TNGX

Tango Therapeutics (TNGX)

Tango Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:TNGX
DatumZeitQuelleÜberschriftSymbolFirma
02/01/202513h07Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TNGXTango Therapeutics Inc
03/12/202413h00Business WireTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TNGXTango Therapeutics Inc
27/11/202413h00Business WireTango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:TNGXTango Therapeutics Inc
20/11/202422h24Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:TNGXTango Therapeutics Inc
19/11/202401h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
08/11/202403h35Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TNGXTango Therapeutics Inc
07/11/202403h40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TNGXTango Therapeutics Inc
06/11/202413h43Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TNGXTango Therapeutics Inc
06/11/202413h23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNGXTango Therapeutics Inc
06/11/202413h05Business WireTango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
06/11/202413h00Business WireTango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development ProgramNASDAQ:TNGXTango Therapeutics Inc
28/10/202414h22Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TNGXTango Therapeutics Inc
26/10/202403h30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TNGXTango Therapeutics Inc
26/10/202403h30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TNGXTango Therapeutics Inc
23/10/202402h50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TNGXTango Therapeutics Inc
23/10/202402h48Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
22/10/202418h03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TNGXTango Therapeutics Inc
28/08/202413h00Business WireTango Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:TNGXTango Therapeutics Inc
07/08/202413h13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TNGXTango Therapeutics Inc
07/08/202413h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNGXTango Therapeutics Inc
07/08/202413h00Business WireTango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
07/06/202423h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
07/06/202423h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
07/06/202423h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
06/06/202422h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNGXTango Therapeutics Inc
05/06/202413h00Business WireTango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:TNGXTango Therapeutics Inc
23/05/202415h18PR Newswire (US)Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical programNASDAQ:TNGXTango Therapeutics Inc
23/05/202413h18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNGXTango Therapeutics Inc
23/05/202413h00Business WireTango Therapeutics Announces Discontinuation of TNG348 ProgramNASDAQ:TNGXTango Therapeutics Inc
08/05/202413h21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TNGXTango Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TNGX

Kürzlich von Ihnen besucht

NASDAQ
GOOGL
Alphabet
TG
DBK
Deutsche Bank
DBI
SDXP
SDAX
AMEX
XLF
Financial Select Sector
COIN
SOLUSD
Solana
COIN
ETHUSD
Ethereum
DBI
MDAX
MDAX
TG
BAS
BASF
NASDAQ
TSLA
Tesla
COIN
AVAXUSD
Avalanche
NYSE
JPM
JP Morgan Chase
NYSE
KO
Coca Cola
CCOM
SILVER
SILVER
TG
BAYN
Bayer
USOTC
DTEGY
Deutsche Telekom (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten